Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07706855Phase 1Not Yet Recruiting

Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

Role: lead

NCT07845266Phase 1Completed

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma

Role: lead

NCT07777211Phase 1Active Not Recruiting

A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

Role: lead

NCT07209813Phase 2Recruiting

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Role: lead

NCT07713290Phase 1Active Not Recruiting

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

Role: lead

NCT07704515Phase 1Not Yet Recruiting

GKL-006Allo Injection in Patients With Advanced Solid Tumors

Role: lead

NCT05962450Phase 2Unknown

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Role: collaborator

All 7 trials loaded